OVERSEA CHINESE BANKING Corp Ltd Purchases 39,688 Shares of DexCom, Inc. (NASDAQ:DXCM)

OVERSEA CHINESE BANKING Corp Ltd increased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 579.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 46,543 shares of the medical device company's stock after buying an additional 39,688 shares during the period. OVERSEA CHINESE BANKING Corp Ltd's holdings in DexCom were worth $3,176,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Golden State Wealth Management LLC raised its holdings in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares in the last quarter. Optiver Holding B.V. bought a new stake in shares of DexCom in the 4th quarter worth approximately $33,000. TD Private Client Wealth LLC raised its holdings in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares in the last quarter. Heck Capital Advisors LLC bought a new stake in shares of DexCom in the 4th quarter worth approximately $38,000. Finally, Alpine Bank Wealth Management bought a new stake in shares of DexCom in the 1st quarter worth approximately $40,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

NASDAQ:DXCM traded down $0.03 during trading hours on Thursday, hitting $84.10. 4,777,194 shares of the company traded hands, compared to its average volume of 4,427,092. The stock has a market capitalization of $32.98 billion, a price-to-earnings ratio of 62.76, a P/E/G ratio of 1.81 and a beta of 1.44. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.19. The firm has a 50-day moving average of $84.53 and a 200 day moving average of $80.09. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 12.90% and a return on equity of 30.05%. DexCom's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.32 earnings per share. On average, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the completion of the transaction, the executive vice president owned 95,602 shares in the company, valued at approximately $8,057,336.56. This represents a 9.47% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,190 shares of company stock valued at $2,281,732 in the last 90 days. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DXCM. Cfra Research raised shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Robert W. Baird lowered their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Canaccord Genuity Group boosted their price objective on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Piper Sandler lowered their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Finally, Morgan Stanley boosted their price objective on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research report on Tuesday. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, DexCom currently has an average rating of "Moderate Buy" and an average target price of $99.60.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.